Moreover, histone deacetylase inhibitors have been evaluated in castration-resistant prostate cancer (CRPC) or chemotherapy-resistant prostate cancer due to their effects on the expression of the androgen receptor gene. This evidence concerns the gene AR and Familial prostate cancer.